The majority of antidepressant drugs act by increasing synaptic serotonin levels in the brain. Genetic variation in serotonin-related genes may therefore influence antidepressant efficacy. In this study, nine polymorphisms in four serotonin receptor genes (HTR1B, HTR2A, HTR5A and HTR6) and the serotonin transporter gene (SLC6A4) were analysed to investigate their influence on antidepressant response in a well-characterized unipolar depressive population (n ¼ 166) following a protocolized treatment regimen. 5-HTTLPR short-allele homozygotes were significantly associated with both remission (odds ratios (OR) ¼ 4.00, P ¼ 0.04) and response (OR ¼ 5.06, P ¼ 0.02) following second switch treatment, with a similar trend observed following initial treatment and paroxetine therapy. Following initial treatment, unipolar patients homozygous for the SLC6A4 intron 2 repeat polymorphism were significantly associated with lack of remission (OR ¼ 0.38, P ¼ 0.02) and lack of response (OR ¼ 0.42, P ¼ 0.01). Additionally, the HTR2A C 1354 T polymorphism showed an association with remission (OR ¼ 7.50, P ¼ 0.002) and response (OR ¼ 5.25, P ¼ 0.01) following paroxetine therapy. These results suggest that genetically determined variation in serotonin receptor genes makes a significant contribution to the efficacy of commonly prescribed antidepressant drugs.
Introduction
Serotonin receptors can be directly targeted by antidepressants, for example imipramine directly antagonizes the serotonin receptor 2A (HTR2A), whereas clomipramine and mianserin have been shown to target serotonin receptor 6 (HTR6). 1 The majority of serotonin receptors are G-protein-coupled receptors that modulate intra-cellular levels of cAMP.
The majority of studies investigating the association between genetic variations in the serotonin genes and antidepressant response have analysed polymorphisms in the serotonin transporter gene (SLC6A4), which is targeted by selective serotonin reuptake inhibitors (SSRIs) and the majority of tricyclic antidepressants (TCAs). 2 The SLC6A4 gene is located on chromosome 17q11.1-q12, spans 31 kb, consists of 14 exons and encodes a 630 amino-acid protein. 3 Two common polymorphisms have been shown to affect expression of SLC6A4: a 44 bp deletion/insertion polymorphism (5-HTTLPR) in the 5 0 flanking regulatory region of the SLC6A4 gene and a second variable number of tandem repeats (VNTR) polymorphism in intron 2. This VNTR polymorphism consists of 9, 10 or 12 copies of a 16-17 bp repeat element.
The serotonin system plays a central role in the action of antidepressant drugs. Genetic variation that may affect the integrity of this system may therefore influence treatment response. In this study, we have investigated a number of polymorphisms in a variety of serotonin receptor genes to determine whether inheritance of specific polymorphisms is associated with response to a variety of commonly prescribed antidepressants.
Results

5-HTTLPR
Initial therapy. Following initial drug treatment, a higher frequency of 5-HTTLPR short-allele homozygotes was observed in responders compared to non-responders (29 vs 19% , w 2 ¼ 2.77, P ¼ 0.25), although this failed to reach significance. Similarly, no significant differences in genotype distribution were associated with remission (w 2 ¼ 0.25, P ¼ 0.88) or adverse drug reaction (ADR) incidence (w 2 ¼ 2.52, P ¼ 0.28) (Table 1A) .
Second switch therapy. Significant differences in 5-HTTLPR genotype frequencies were observed following second switch treatment (Table 1A) . Inheritance of two copies of the 5-HTTLPR short allele was associated with both remission (w 2 ¼ 5.98, P ¼ 0.05) and response (w 2 ¼ 7.40, P ¼ 0.025) following longer-term treatment, while a higher frequency of heterozygotes was found in the non-remission and non-response groups (Table 1A) . These results suggest a recessive mode of action for the short allele, with homozygotes associated with remission (odds ratios (OR) ¼ 4.00, P ¼ 0.04) and response (OR ¼ 5.06, P ¼ 0.02) (Table 2b) . 5-HTTLPR genotype did not influence ADR incidence (w 2 ¼ 0.39, P ¼ 0.82).
Paroxetine therapy. Following paroxetine treatment, the 5-HTTLPR short/short genotype was more frequent in responders compared to non-responders (40 vs 19%, w 2 ¼ 4.20, P ¼ 0.12) and in remitters compared to nonremitters (38 vs 24%, w 2 ¼ 2.24, P ¼ 0.33). However, due to lower number of patients in this group, these figures failed to reach significance. ADRs following paroxetine therapy were not influenced by 5-HTTLPR genotype (w 2 ¼ 2.94, P ¼ 0.23).
Early onset depressive population. The 5-HTTLPR short-allele homozygotes genotype was more frequent in patients responding to antidepressant treatment (28 vs (Table 1B) . In both cases, the frequency of individuals carrying two copies of the 12-copy repeat was significantly associated with lack of remission (OR ¼ 0.38, P ¼ 0.02) and lack of response (OR ¼ 0.42, P ¼ 0.01) (Table 2A) Paroxetine therapy. HTR2A C 1354 T heterozygotes were significantly associated with improved response to paroxetine therapy. There was a significantly higher frequency of heterozygotes in the remitter and response groups in comparison to the non-remitter (OR ¼ 7.50, P ¼ 0.002) and non-response groups (OR ¼ 5.25, P ¼ 0.01) ( Table 2C) . The HTR2A C 102 T genotype did not influence remission (w 2 ¼ 0.65, P ¼ 0.72) or response (w 2 ¼ 1.36, P ¼ 0.51) but was associated with the incidence of ADRs (w 2 ¼ 9.73, P ¼ 0.008) following paroxetine treatment with patients inheriting the HTR2A C 102 C genotype associated with the incidence of ADRs (OR ¼ 24.69, P ¼ 0.007). Table 1 illustrates that no significant difference in genotype frequency between response groups was observed for any polymorphisms in the remaining 5-HT receptor genes.
Discussion
The serotonin system is targeted by antidepressants. Our hypothesis was that genetic variation in genes influencing serotonin signalling cascades may therefore be associated with antidepressant response.
We demonstrated a significant association between 5-HTTLPR short-allele homozygotes and both remission and response following second switch drug therapy. In support of these findings, a similar association was observed in a second distinct and pathologically different depressive population.
This observation has previously been reported in three studies. Kim et al. 4 reported that the 5-HTTLPR short/short genotype was more frequent in responders to either fluoxetine or paroxetine treatment (64 vs 36%, P ¼ 0.007).
They also observed an increase in heterozygotes in nonresponders (58 vs 32%), suggesting that the short allele was acting in a recessive manner. A second study of 66 depressed Japanese patients also found that short-allele homozygotes were more frequent in responders to fluvoxamine (69 vs 32%, P ¼ 0.01). Again, heterozygote frequencies were higher in non-responders (47 vs 31%) which further suggests a recessive allele effect. 5 Both these studies were, however, carried out in Oriental populations where the frequencies of the 5-HTTLPR genotypes differ from Caucasian populations, with the short/short genotype frequency approximately 25% in Caucasian populations but 57% in Asian populations. 2 However, a recent study using a mixed American population (78% Caucasians, 6% African American, 7% Hispanic, 5% Asian and 3% other) also found the short allele to be associated with response to fluoxetine. 6 In contrast to these findings, the majority of previous studies investigating the inheritance of 5-HTTLPR genotype on antidepressant efficacy have found the short allele to be associated with reduced antidepressant response. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] This may be explained by a number of variables that differ between the studies. First, variation in the criteria used to measure response has differed between studies, with a reduction of 50% or more from baseline Hamilton Depression Rating Scale (HAMD) scores used in certain studies, 4, 5, 7, 13, [15] [16] [17] but an HAMD score of 8 or less was used to determine response in other studies. 8, 12 In addition, a further criterion for response was used in certain studies where differences in HAMD score were analysed before and after treatment. 11, 14, 18 Such differences in determining response may potentially lead to situations where one individual may be classified as a responder in one study but as a non-responder in another. Our study assessed both response and remission to eliminate this variability and found the 5-HTTLPR short-allele homozygotes to be more frequent in both groups. 
Polymorphisms and antidepressant response
Second, inclusion criteria have also differed between studies, for example some studies included bipolar patients, 10 others unipolar 12,13,15 and some both. 11 These differences may result in variation in response, for example bipolar patients going through a manic phase may be observed as antidepressant responders. By analysing early onset and unipolar depressive populations, we have confirmed that the 5-HTTLPR genotype has the same effect in two separate depressive populations.
A third variable differing between studies was the time point at which HAMD scores were evaluated. A number of studies determined response after 4 weeks, 11,17,18 6 weeks 4, 5, 8, 12 or had multiple time points when the HAMD score was measured. [13] [14] [15] [16] Response in our study was assessed following initial therapy that gave an indication of how genotype influenced initial drug treatment, while the effect on longer-term treatment was assessed following second switch therapy.
To assess whether there were inherent differences in depression scores in our responsive and non-responsive patients, baseline HAMD scores were compared in responders/ non-responders, remitters/non-remitters and in patients suffering/not suffering ADRs following both initial and second switch therapy (Table 4) . Although significant differences in HAMD scores were observed between remitters/ non-remitters and responders/non-responders, we do not believe that these represent true clinical differences between response groups. In addition, as we did not observe similar associations for all genotypes tested, we are confident that our results do not simply reflect inherent differences in depression severity.
In comparison to the 5-HTTLPR polymorphism, only two studies have previously investigated the effect of the SLC6A4 intron 2 polymorphism on antidepressant response. Kim et al. 4, 19 found the 12-copy repeat to be associated with paroxetine and fluoxetine response in 120 depressed Koreans, although a Japanese study found no association with this polymorphism and fluvoxamine response. Our findings suggest that individuals homozygous for the 12-copy repeat are more likely to have a poor therapeutic outcome following antidepressant treatment.
The difference in results between our study and Kim et al.'s findings may be due to the differences in allele frequencies between Oriental and Caucasians populations. The frequency for the 12-copy allele homozygotes was 42% in our study, but 81% in the Korean population 4 and 71% in a Japanese population. 19 The 12-copy allele of the SLC6A4 intron 2 polymorphism has been associated with increased gene transcription 20, 21 and the 5-HTTLPR short allele with reduced transcription. 22 , 23 We have shown that 5-HTTLPR short-allele homozygotes are associated with favourable response, while homozygotes for the SLC6A4 intron 2 12-copy allele are associated with poorer response, suggesting that increased transcription of the SLC6A4 gene results in a higher probability of poor antidepressant response.
The polymorphisms in the SLC6A4 gene showed the same trend independent of the population analysed, suggesting that these polymorphisms influence response irrespective of time and drug type. However, when response to paroxetine was analysed, two further polymorphisms in the HTR2A Early onset depressive patients were often prescribed more than one medication before clinical response was measured.
c Remission and ADR were not measured in this population.
Polymorphisms and antidepressant response gene showed significant associations to therapeutic outcome suggesting a paroxetine-specific action. A number of studies have provided evidence that the HTR2A receptor is involved in susceptibility to depression and in achieving antidepressant response. The first of these showed the HTR2A receptor to be overexpressed in depressed patients. 24 A further study showed that downregulation of this receptor was observed after paroxetine therapy. 25 Stress activates HTR2A receptors and this has been shown to down-regulate the downstream brain-derived neurotrophic factor (BDNF) in rat models. [26] [27] [28] BDNF has been shown to be upregulated following antidepressant treatment and downregulated in depressed subjects. 29, 30 Levels of BDNF were decreased in the rat hippocampus following HTR2A agonist treatment, an effect which was blocked when an HTR2A antagonist was administered. 31 Finally, imipramine, nefazodone and mirtazapine directly antagonize HTR2A in vitro and antidepressants may therefore exert their function by antagonizing HTR2A receptors. 28, 32 We found a significant association between HTR2A C 1354 T genotype and both remission and response to paroxetine. This polymorphism results in a histidine to tyrosine aminoacid change at position 452. It was expected that the HTR2A T 1354 T homozygotes would have been associated with better paroxetine response, although no differences in this genotype were seen between responders and non-responders to paroxetine or SSRIs as a whole, suggesting that the heterozygote phenotype differs in a non-additive-dependent manner.
The HTR2A C 1354 T single nucleotide polymorphism (SNP) has only been studied as a modifier of antidepressant response in two previous reports. The first one found no association in depressed patients (n ¼ 173) given a variety of antidepressant treatments, 18 however the second report found the HTR2A T 1354 allele to be associated with response to fluoxetine. 6 This suggests that the HTR2A C 1354 T polymorphism influences the efficacy of only SSRIs, an observation that was also made in this study. Further studies investigating this allele and response to SSRIs are warranted.
The HTR2A C 102 T polymorphism showed a possible association with susceptibility to ADRs following paroxetine treatment, however the small number of patients suffering an ADR means this finding must be treated with caution. A previous study investigating the HTR2A C 102 T polymorphism and antidepressant efficacy found the same association, where individuals carrying the HTR2A C 102 C genotype were more likely to suffer an ADR following paroxetine, but not mirtazapine therapy. 32 The HTR2A C 102 T polymorphism did not, however, influence response or remission to antidepressant therapy in this patient group, a finding also described by Cusin et al. 33 when investigating the influence of this polymorphism on the efficacy of fluvoxamine and paroxetine.
In conclusion, we found significant associations between the 5-HTTLPR and SLC6A4 intron 2 genotypes with both remission and response following initial and second switch therapy. These findings conflict with a number of previously published studies and add to the heterogeneity of observations in pharmacogenetic studies analysing SLC6A4 polymorphisms. A number of possible confounding factors (for example, axis II comorbidity, drug plasma levels) were not recorded in this and previous similar studies, while other potential confounding factors (specific psychotherapy interventions, antipsychotic medications) were not used in patients in this study, all of which may go some way to rationalize differences in reported results. However, the patient group and treatment regimen used in this study is representative of routine clinical practice in the United Kingdom. It has been suggested that many patients recruited to previous antidepressant trials represent only a minority of patients treated for depression in routine clinical practice. 34, 35 For pharmacogenetics to be used as a prognostic tool to facilitate the development of personalized medicine, we must be able to demonstrate that genetic factors can influence therapeutic response under 'real-world' conditions. It is also of obvious importance that our observations are replicated in larger, independently recruited patient groups, particularly as the present study involved the simultaneous analysis of multiple SNPs.
Materials and methods
Subjects Unipolar depressive population. Patients diagnosed with unipolar depression (n ¼ 166) were recruited from the Affective Disorder Clinic (ADC) in the Department of Psychiatry at Ninewells Hospital, Dundee, UK. Entry criteria was an age of between 18 and 65 years and diagnosis of unipolar depression by ICD-10 criteria, with a minimum Hamilton score of 18. All patients were of Caucasian descent (52 men, 114 women, mean age 43.42 ± 11.34 years) and were treated according to a protocolized regimen. The aim of the research clinic was to prospectively identify a cohort of patients with treatment-resistant depression (defined as failure to respond to adequate dose and duration of two antidepressants). Exclusion criteria were contraindications to drug therapy including pregnancy, lactation and severe physical disorder. Patients were treated following a protocolized regimen. Prior to referral to the ADC, the majority of patients had been prescribed antidepressants by their GP or community mental health team but at an inadequate dose. The first step of the ADC protocol was therefore to optimize any ongoing antidepressant therapy, that is prescribe the maximum tolerated dose for a minimum of 6 weeks. Lack of response to this initial therapy resulted in a trial of an SSRI antidepressant (paroxetine up to 50 mg per day or citalopram up to 60 mg per day if paroxetine was not tolerated). Lack of response to paroxetine resulted in the TCA imipramine being prescribed (up to 300 mg per day) or lofepramine (up to 280 mg per day) if imipramine was not tolerated. If the initial therapy was already with an SSRI then the second treatment trial was with a TCA. Lack of response to imipramine or lofepramine Each treatment was prescribed for a minimum of 6 weeks before clinical assessment. The HAMD was used to determine mental status and therapeutic response following initial therapy at least 6 weeks following commencement of treatment. Second switch therapy was assessed at a minimum of 18 weeks. Response was defined as a 50% or greater reduction from baseline HAMD score with remission defined as an HAMD score of 7 or less. Occurrence of ADRs was also recorded. Any patient who reached second switch treatment had been exposed, prospectively, to an adequate dose and duration of at least two antidepressants and was deemed to be treatment resistant.
Early onset depressive population. Patients with early onset depression (n ¼ 102) were recruited from the Department of Psychiatry at the Royal Edinburgh Hospital. Patients were diagnosed as suffering from early onset unipolar or bipolar depression according to Diagnostic and Statistical Manual of Mental Disorders, fourth edition criteria [36] [37] [38] [39] with a maximum age of 22. Twenty-one subjects of the early onset depressed population were diagnosed with bipolar depression with the remainder (81 patients) diagnosed with unipolar depression.
Antidepressant response data were collected for 70 early onset unipolar patients. Criteria for response included a formal HAMD rating score at 12 weeks, as well as an assessment of previous history of treatment response obtained from patient notes.
Following written informed consent, whole blood was collected from all study participants and stored in EDTA anti-coagulated blood tubes at À20 1C prior to further analysis.
Ethics
The study was approved by the Tayside Committee on Medical Research Ethics and the Lothian Research Ethics Committee. Written informed consent was obtained from all study participants.
Clinical data
Clinical response data were obtained for 163 unipolar patients from Dundee with data for 3 patients unobtainable. The number and type of antidepressant drugs prescribed following initial and second switch therapy are summarized in Table 4A, while Table 4B details the number of patients remitting, responding or suffering an ADR following initial and second switch drug therapy. The number of patients receiving second switch treatment was lower than following initial therapy due to patients responding to previous drug treatments and/or reduced patient compliance. In total, 19 patients did not respond to initial therapy and failed to return to the ADC. A further 16 patients failed to respond to initial and first switch therapy and did not return to the ADC for second switch treatment.
Analysis of clinical outcome following treatment with the most commonly prescribed drug, paroxetine, was also carried out to determine if polymorphisms in serotonin transporter and receptor genes influenced response specifically to paroxetine therapy. A total of 70 clinical data sets were collected from early onset depressive patients. Table 4A and B detail the number and type of antidepressant drugs prescribed to these individuals and the number of responders and nonresponders to drug treatment. It was not possible to collect remission or ADR data for this population due to differences in study parameters between the collection centres.
Molecular analysis DNA was extracted from 200 ml of whole blood using a QIAamp DNA Blood Kit (Qiagen, Crawley, West Sussex, UK) according to the manufacturer's instructions.
Genotyping for HTR1B A À161 T(rs130058), HTR1B C 816 G(rs6296), HTR6 C 267 T(rs1805054), 5-HTTLPR and the SLC6A4 intron 2 polymorphism was carried out as previously described. 4, 40, 41 Novel PCR-restriction fragment length polymorphism (RFLP) assays were designed for the polymorphisms HTR2A C 1354 T(rs6314), HTR2A T 102 C(rs6313), HTR5A G À19 C and HTR5A A 12 T(rs6320). Table 5 summarizes the PCR protocols and amplification conditions as well as primer sequences, restriction enzymes and digest products for each of these assays. RFLP products between 150 and 800 bp were viewed on 2% agarose gels and smaller products on 8% polyacrylamide gels stained with ethidium bromide. All gels were visualized using a UV transilluminator at 302 nm.
Statistical analysis
Genotype frequencies between response and non-response groups using 3 by 2 contingency tables were compared using w 2 -tests. Further analysis was performed when the distribution of genotype frequencies differed between response groups (w 2 45.00). Genotype influence on response was analysed using the Fisher's exact test and presented as OR with 95% confidence intervals (CI).
All statistical analysis was carried out using InStat Version 3.0a for Macintosh (GraphPad Software, CA, USA).
Nucleotide sequences
All nucleotide sequences are numbered such that nucleotide 1 corresponds to A of the ATG start codon and all aminoacid sequences are numbered such that amino acid 1 refers to the first amino acid in the protein sequence. All sequences were obtained from the NCBI database (http:// www.ncbi.nlm.nih.gov/) with the accession numbers SLC6A4-AF117826; HTR1B-M83180; HTR2A-NM_000621; HTR5A-X81411 and HTR6-NM_000871.
